These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 25072544

  • 1. [Metabolic therapy for heart failure].
    Loiacono F, Alberti L, Lauretta L, Puccetti P, Silipigni C, Margonato A, Fragasso G.
    Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
    [Abstract] [Full Text] [Related]

  • 2. Metabolic therapy of heart failure.
    Fragasso G, Salerno A, Spoladore R, Bassanelli G, Arioli F, Margonato A.
    Curr Pharm Des; 2008; 14(25):2582-91. PubMed ID: 18991675
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure.
    Fragasso G.
    Int J Clin Pract; 2007 Apr; 61(4):603-10. PubMed ID: 17394434
    [Abstract] [Full Text] [Related]

  • 4. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
    Lopaschuk GD.
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):228-30. PubMed ID: 16959756
    [Abstract] [Full Text] [Related]

  • 5. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [Abstract] [Full Text] [Related]

  • 6. Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.
    Fragasso G.
    Card Fail Rev; 2016 May; 2(1):8-13. PubMed ID: 28785448
    [Abstract] [Full Text] [Related]

  • 7. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD.
    Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [Abstract] [Full Text] [Related]

  • 8. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ, Mishra S.
    Indian Heart J; 2017 Feb; 69(3):393-401. PubMed ID: 28648439
    [Abstract] [Full Text] [Related]

  • 9. Prognostic relevance of metabolic approach in patients with heart failure.
    Di Napoli P, Barsotti A.
    Curr Pharm Des; 2009 Feb; 15(8):883-92. PubMed ID: 19275652
    [Abstract] [Full Text] [Related]

  • 10. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D.
    Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
    [Abstract] [Full Text] [Related]

  • 11. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.
    Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vinereanu D, Hamid MA, Jourdain P, Ponikowski P.
    Int J Cardiol; 2016 Jan 15; 203():909-15. PubMed ID: 26618252
    [Abstract] [Full Text] [Related]

  • 12. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
    Rosano GM, Vitale C, Fragasso G.
    Am J Cardiol; 2006 Sep 04; 98(5A):14J-18J. PubMed ID: 16931201
    [Abstract] [Full Text] [Related]

  • 13. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD.
    Presse Med; 1998 Dec 12; 27(39):2100-4. PubMed ID: 9893703
    [Abstract] [Full Text] [Related]

  • 14. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr 12; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 15. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
    Fragasso G, Spoladore R, Cuko A, Palloshi A.
    Curr Clin Pharmacol; 2007 Sep 12; 2(3):190-6. PubMed ID: 18690865
    [Abstract] [Full Text] [Related]

  • 16. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
    O'Meara E, McMurray JJ.
    Heart; 2005 Feb 12; 91(2):131-2. PubMed ID: 15657211
    [Abstract] [Full Text] [Related]

  • 17. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
    Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM.
    Can J Physiol Pharmacol; 2007 May 12; 85(5):527-35. PubMed ID: 17632588
    [Abstract] [Full Text] [Related]

  • 18. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
    Wenmeng W, Qizhu T.
    Med Hypotheses; 2011 Feb 12; 76(2):181-3. PubMed ID: 20932648
    [Abstract] [Full Text] [Related]

  • 19. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H, Zarain-Herzberg A, Maisch B.
    Herz; 2002 Nov 12; 27(7):621-36. PubMed ID: 12439634
    [Abstract] [Full Text] [Related]

  • 20. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC, Marzilli M.
    Fundam Clin Pharmacol; 2003 Apr 12; 17(2):133-45. PubMed ID: 12667223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.